China Medical Technologies left $426 million of bonds unpaid amid an alleged $355 million insider fraud
China Medical Technologies · Medical devices (listed, Nasdaq)
The case in brief
Visible before detection
Checks that could have surfaced it, on hindsight
Ownership / related-party links
Would have linked acquisition sellers to the CEO.
Can mislead when: Nominee directors and offshore layers hide links. Name matching throws up false positives, so every flag shows its evidence path.
End-use tracing of funds
Would have traced bond proceeds.
Can mislead when: Kubr sees only the company's own accounts. Once money reaches a third party's bank, Kubr can flag the payee but cannot see the next hop without that party's consent.
Bank credits vs books
Would have checked cash balances with banks.
Can mislead when: AA only sees the accounts the company links, so an undisclosed account stays invisible. Cash-heavy businesses and timing differences create false flags.
Where Kubr services would have helped
Borrower monitor
Offered in India- C1 Would have checked cash balances with banks.
- C3 Would have linked acquisition sellers to the CEO.
- C6 Would have traced bond proceeds.
Proceeds tracer
Offered in India- C1 Would have checked cash balances with banks.
- C3 Would have linked acquisition sellers to the CEO.
- C6 Would have traced bond proceeds.
Financial diligence
Offered in India- C1 Would have checked cash balances with banks.
- C3 Would have linked acquisition sellers to the CEO.
Portfolio monitor
Offered in India- C1 Would have checked cash balances with banks.
- C3 Would have linked acquisition sellers to the CEO.
Mapped from the checks each service runs. A hindsight reading of public records, not a promise that the failure would have been found.
Same pattern
A summary of public documents. It reports what the sources say. It is not Kubr's finding and not a statement of guilt.